Vol. 25 No. 3 (2021)
ACQUIRED HEART DISEASES

Short-term outcomes of surgical atrial ablation and septal myectomy

PDF (Русский)
  • A.S. Zalesov,
  • A.V. Bogachev-Prokophiev,
  • A.V. Afanasyev,
  • R.M. Sharifulin,
  • A.V. Sapegin,
  • S.A. Budagaev,
  • S.I. Zheleznev,
  • I.I. Demin
A.S. Zalesov
Meshalkin National Medical Research Center, Novosibirsk
Bio
A.V. Bogachev-Prokophiev
Meshalkin National Medical Research Center, Novosibirsk
A.V. Afanasyev
Meshalkin National Medical Research Center, Novosibirsk
R.M. Sharifulin
Meshalkin National Medical Research Center, Novosibirsk
A.V. Sapegin
Meshalkin National Medical Research Center, Novosibirsk
S.A. Budagaev
Meshalkin National Medical Research Center, Novosibirsk
S.I. Zheleznev
Meshalkin National Medical Research Center, Novosibirsk
I.I. Demin
Meshalkin National Medical Research Center, Novosibirsk
DOI: https://doi.org/10.21688/1681-3472-2021-3-51-60

Published 2021-09-28

Keywords

  • atrial fibrillation,
  • hypertrophic cardiomyopathy,
  • septal myectomy,
  • surgical ablation

How to Cite

Zalesov, A., Bogachev-Prokophiev, A., Afanasyev, A., Sharifulin, R., Sapegin, A., Budagaev, S., Zheleznev, S., & Demin, I. (2021). Short-term outcomes of surgical atrial ablation and septal myectomy. Patologiya Krovoobrashcheniya I Kardiokhirurgiya, 25(3), 51–60. https://doi.org/10.21688/1681-3472-2021-3-51-60

Copyright (c) 2021 Zalesov A.S., Bogachev-Prokophiev A.V., Afanasyev A.V., Sharifulin R.M., Sapegin A.V., Budagaev S.A., Zheleznev S.I., Demin I.I.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Background. Hypertrophic cardiomyopathy is one of the most common types of cardiomyopathy. The appearance of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy is associated with significant clinical worsening. Outcomes of surgical ablation and septal myectomy in these patients are limited.
Aim. This retrospective study aimed to evaluate short-term outcomes of concomitant surgical ablation and septal myectomy in patients with obstructive hypertrophic cardiomyopathy and atrial fibrillation.
Methods. Fifty-five patients with hypertrophic obstructive cardiomyopathy and atrial fibrillation who underwent concomitant surgical ablation and septal myectomy between 2014 and 2019 were analysed. Patients with paroxysmal atrial fibrillation predominantly underwent left atrial ablation, and those with nonparoxysmal atrial fibrillation predominantly underwent the Maze IV procedure. Surgical ablation was performed using cryoablation alone (83.6%) or in combination with radiofrequency energy (16.4%).
Results. Hospital mortality was 1.8%. Incidence of major adverse events was 3.6%. Sinus node dysfunction and atrioventricular block occurred in 7.3% and 1.8% of patients, respectively. Bleeding requiring revision occurred in 2 (3.6%) patients. Forty-nine (89.1%) patients had stable sinus rhythm and five (9.1%) were on dual-chamber pacemaker stimulation at the time of discharge.
Conclusion. Concomitant septal myectomy and surgical ablation are feasible and safe in patients with hypertrophic obstructive cardiomyopathy and atrial fibrillation.

Received 5 April 2021. Revised 16 May 2021. Accepted 17 May 2021.

Funding: The study did not have sponsorship.

Conflict of interest: The authors declare no conflicts of interests.

Contribution of the authors
Conception and study design: A.S. Zalesov, A.V. Bogachev-Prokophiev
Data collection and analysis: A.S. Zalesov, S.A. Budagaev, A.V. Sapegin
Statistical analysis: A.S. Zalesov, A.V. Afanasyev, R.M. Sharifulin
Drafting the article: A.S. Zalesov
Critical revision of the article: A.V. Bogachev-Prokophiev, S.I. Zheleznev, I.I. Demin
Final approval of the version to be published: A.S. Zalesov, A.V. Bogachev-Prokophiev, A.V. Afanasyev, R.M. Sharifulin, A.V. Sapegin, S.A. Budagaev, S.I. Zheleznev, I.I. Demin

PDF (Русский)

References

  1. Ommen S.R., Mital S., Burke M.A., Day Sh.M., Deswal A., Elliott P., Evanovich L.L., Hung J., Joglar J.A., Kantor P., Kimmelstiel C., Kittleson M., Link M.S., Maron M.S., Martinez M.W., Miyake C.Y., Schaff H.V., Semsarian C., Sorajja P. 2020 AHA / ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: Executive summary: A report of the American College of Cardiology / American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;142(25):e533-e557. PMID: 33215938. https://doi.org/10.1161/CIR.0000000000000938
  2. Maron B.J. Hypertrophic Cardiomyopathy. In: Bonow R.O., Mann D.P., Zipes D.P., Libby P., editors. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. Vol. 1. 9th ed. Philadelphia: Elsevier Saunders Publ.; 2011. рp. 1582-1594.
  3. Olivotto I., Cecchi F., Casey S.A., Dolara A., Traverse J.H., Maron B.J. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104(21):2517-2524. PMID: 11714644. https://doi.org/10.1161/hc4601.097997
  4. Maron B.J., Olivotto I., Bellone P., Conte M.R., Cecchi F., Flygenring B.P., Casey S.A., Gohman T.E., Bongioanni S., Spirito P. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;39(2):301-307. PMID: 11788223. https://doi.org/10.1016/s0735-1097(01)01727-2
  5. MacIntyre C., Lakdawala N.K. Management of atrial fibrillation in hypertrophic cardiomyopathy. Circulation. 2016;133(19):1901-1905. PMID: 27166348. https://doi.org/10.1161/CIRCULATIONAHA.115.015085
  6. Patten M., Pecha S., Aydin A. Atrial fibrillation in hypertrophic cardiomyopathy: diagnosis and considerations for management. J Atr Fibrillation. 2018;10(5):1556. PMID: 29988228; PMCID: PMC6006972. https://doi.org/10.4022/jafib.1556
  7. Габрусенко С.А., Гудкова А.Я., Козиолова Н.А., Александрова С.А., Берсенева М.И., Гордеев М.Л., Дземешкевич С.Л., Заклязьминская Е.В., Иртюга О.Б., Каплунова В.Ю., Костарева А.А., Крутиков А.Н., Маленков Д.А., Новикова Т.Н., Саидова М.А., Санакоев М.К., Стукалова О.В. Гипертрофическая кардиомиопатия. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(5):4541. [Gabrusenko S.A., Gudkova A.Ya., Koziolova N.A., Alexandrova S.A., Berseneva M.I., Gordeev M.L., Dzemeshkevich S.L., Zaklyazminskaya E.V., Irtyuga O.B., Kaplunova V.Yu., Kostareva A.A., Krutikov A.N., Malenkov D.A., Novikova T.N., Saidova M.A., Sanakoev M.K., Stukalova O.V. 2020 Clinical practice guidelines for Hypertrophic cardiomyopathy. Russian Journal of Cardiology. 2021;26(5):4541. (In Russ.)] https://doi.org/10.15829/1560-4071-2021-4541
  8. Authors / Task Force members, Elliott P.M., Anastasakis A., Borger M.A., Borggrefe M., Cecchi F., Charron P., Hagege A.A., Lafont A., Limongelli G., Mahrholdt H., McKenna W.J., Mogensen J., Nihoyannopoulos P., Nistri S., Pieper P.G., Pieske B., Rapezzi C., Rutten F.H., Tillmanns C., Watkins H. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-2779. PMID: 25173338. https://doi.org/10.1093/eurheartj/ehu284
  9. Guttmann O.P., Rahman M.S., O'Mahony C., Anastasakis A., Elliott P.M. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart. 2014;100(6):465-472. PMID: 24014282. https://doi.org/10.1136/heartjnl-2013-304276
  10. Schaff H.V., Said S.M. Transaortic extended septal myectomy for hypertrophic cardiomyopathy. Oper Tech Thorac Cardiovasc Surg. 2012;17(4):238-250. https://doi.org/10.1053/j.optechstcvs.2012.04.002
  11. Ad N., Damiano R.J. Jr, Badhwar V., Calkins H., La Meir M., Nitta T., Doll N., Holmes S.D., Weinstein A.A., Gillinov M. Expert consensus guidelines: Examining surgical ablation for atrial fibrillation. J Thorac Cardiovasc Surg. 2017;153(6):1330-1354.e1. PMID: 28390766. https://doi.org/10.1016/j.jtcvs.2017.02.027
  12. Siontis K.C., Geske J.B., Ong K., Nishimura R.A., Ommen S.R., Gersh B.J. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population. J Am Heart Assoc. 2014;3(3):e001002. PMID: 24965028; PMCID: PMC4309084. https://doi.org/10.1161/JAHA.114.001002
  13. Sherrid M.V., Barac I., McKenna W.J., Elliott P.M., Dickie S., Chojnowska L., Casey S., Maron B.J. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45(8):1251-1258. PMID: 15837258. https://doi.org/10.1016/j.jacc.2005.01.012
  14. Cappato R., Calkins H., Chen Sh.-A., Davies W., Iesaka Y., Kalman J., Kim Y.-H., Klein G., Natale A., Packer D., Skanes A., Ambrogi F., Biganzoli E. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3(1):32-38. PMID: 19995881. https://doi.org/10.1161/CIRCEP.109.859116
  15. Bassiouny M., Lindsay B.D., Lever H., Saliba W., Klein A., Banna M., Abraham J., Shao M., Rickard J., Kanj M., Tchou P., Dresing T., Baranowski B., Bhargava M., Callahan T., Tarakji K., Cantillon D., Hussein A., Marc Gillinov A., Smedira N.G., Wazni O. Outcomes of nonpharmacologic treatment of atrial fibrillation in patients with hypertrophic cardiomyopathy. Heart Rhythm. 2015;12(7):1438-1447. PMID: 25814420. https://doi.org/10.1016/j.hrthm.2015.03.042
  16. Lapenna E., Pozzoli A., De Bonis M., La Canna G., Nisi T., Nascimbene S., Vicentini L., Di Sanzo S., Del Forno B., Schiavi D., Alfieri O. Mid-term outcomes of concomitant surgical ablation of atrial fibrillation in patients undergoing cardiac surgery for hypertrophic cardiomyopathy. Eur J Cardiothorac Surg. 2017;51(6):1112-1118. PMID: 28329110. https://doi.org/10.1093/ejcts/ezx017
  17. Fitzgerald P., Kusumoto F. The effects of septal myectomy and alcohol septal ablation for hypertrophic cardiomyopathy on the cardiac conduction system. J Interv Card Electrophysiol. 2018;52(3):403-408. PMID: 30097789. https://doi.org/10.1007/s10840-018-0433-0